Brought to you by 
Takeda invests in new biotech Lectus Therapeutics
05 Aug 2004
Executive Summary
Takeda Chemical Industries Ltd. has made an equity investment in Lectus Therapeutics Ltd. (discovering ion-channel modulators) through Takeda Research Investment, the venture capital arm it set up in 2002 to back early-stage biotech companies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda invests in new biotech Lectus Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice